Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219323
Status:
COMPLETED
Last Update Posted:
2011-10-25
First Post:
2005-09-21
Brief Title:
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None